Anticoagulant therapy during the acute phase of non-ST elevation acute coronary syndromes (NSTE-ACS) is strongly recommended by current international guidelines. Evidence supporting the use of anticoagulant therapy in the early phase of NSTE-ACS however, is based on dated trials mostly performed in the nineties and recent randomised clinical trials (RCTs), performed during the last 15 years, clearly evidence a dichotomy in the investigation of antiplatelet and anticoagulant strategies. Many innovations have since occurred in the diagnosis and management of NSTE-ACS. Since a RCT evaluating the efficacy of anticoagulant therapy versus placebo in a contemporary setting of NSTE-ACS management is lacking, we provide a systematic review of 1) the randomised data for ATT in the early phase of NSTE-ACS; 2) modern international guidelines, and 3) contemporary clinical practice data. The results are analysed and potential treatment and research strategies are proposed. (c) 2018 Elsevier B.V. All rights reserved.

Galli, M., Porto, I., Andreotti, F., D'amario, D., Vergallo, R., Della Bona, R., Crea, F., Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives, <<INTERNATIONAL JOURNAL OF CARDIOLOGY>>, 2019; (275): 39-45. [doi:10.1016/j.ijcard.2018.10.087] [http://hdl.handle.net/10807/143259]

Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives

Galli, M.;Porto, I.;Andreotti, F.;Vergallo, R.;Crea, F.
2019

Abstract

Anticoagulant therapy during the acute phase of non-ST elevation acute coronary syndromes (NSTE-ACS) is strongly recommended by current international guidelines. Evidence supporting the use of anticoagulant therapy in the early phase of NSTE-ACS however, is based on dated trials mostly performed in the nineties and recent randomised clinical trials (RCTs), performed during the last 15 years, clearly evidence a dichotomy in the investigation of antiplatelet and anticoagulant strategies. Many innovations have since occurred in the diagnosis and management of NSTE-ACS. Since a RCT evaluating the efficacy of anticoagulant therapy versus placebo in a contemporary setting of NSTE-ACS management is lacking, we provide a systematic review of 1) the randomised data for ATT in the early phase of NSTE-ACS; 2) modern international guidelines, and 3) contemporary clinical practice data. The results are analysed and potential treatment and research strategies are proposed. (c) 2018 Elsevier B.V. All rights reserved.
Inglese
Galli, M., Porto, I., Andreotti, F., D'amario, D., Vergallo, R., Della Bona, R., Crea, F., Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives, <<INTERNATIONAL JOURNAL OF CARDIOLOGY>>, 2019; (275): 39-45. [doi:10.1016/j.ijcard.2018.10.087] [http://hdl.handle.net/10807/143259]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/143259
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 8
social impact